Update on the Role of Rifaximin in Digestive Diseases

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F23%3A00079205" target="_blank" >RIV/00209805:_____/23:00079205 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14110/23:00131030

Result on the web

<a href="https://jgld.ro/jgld/index.php/jgld/article/view/4871" target="_blank" >https://jgld.ro/jgld/index.php/jgld/article/view/4871</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.15403/jgld-4871" target="_blank" >10.15403/jgld-4871</a>

Result language

angličtina

Original language name

Update on the Role of Rifaximin in Digestive Diseases

Original language description

Various environmental factors affecting the human microbiota may lead to gut microbial imbalance and to the development of pathologies. Alterations of gut microbiota have been firmly implicated in digestive diseases such as hepatic encephalopathy, irritable bowel syndrome and diverticular disease. However, while these three conditions may all be related to dysfunction of the gut-liver-brain axis, the precise pathophysiology appears to differ somewhat for each. Herein, current knowledge on the pathophysiology of hepatic encephalopathy, irritable bowel syndrome, and diverticular disease are reviewed, with a special focus on the gut microbiota modulation associated with these disorders during therapy with rifaximin. In general, the evidence for the efficacy of rifaximin in hepatic encephalopathy appears to be well consolidated, although it is less supported for irritable bowel syndrome and diverticular disease. We reviewed current clinical practice for the management of these clinical conditions and underlined the desirability of more real-world studies to fully understand the potential of rifaximin in these clinical situations and obtain even more precise indications for the use of the drug.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30219 - Gastroenterology and hepatology

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2023

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of gastrointestinal and liver diseases

ISSN

1841-8724

e-ISSN

1842-1121

Volume of the periodical

32

Issue of the periodical within the volume

1

Country of publishing house

RO - ROMANIA

Number of pages

18

Pages from-to

92-109

UT code for WoS article

000972987600016

EID of the result in the Scopus database

2-s2.0-85151328387